Antabio SAS
This article was originally published in Start Up
Executive Summary
Antabio SAS is taking an antivirulence rather than an antibiotic approach to treat gram-negative nosocomial infections. When combined with marketed antibiotics, the compounds in its pipeline have potential to target key virulence pathways in pathogenic bacteria, and thus reduce patient mortality and associated costs.